Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
RORγ agonist LYC-55716, a novel small molecule immunotherapy: Rationale for clinical evaluation in non-small cell lung cancer based on translational and bioinformatic evaluation.
Authors
Laura Carter
Lycera Corp., Ann Arbor, MI
Laura Carter, Xikui Liu, Hongxiu Li, Elizabeth Zawidzka, Yilin Gao, Brian Fox, Garry Weems, H. Jeffrey Wilkins, Xiao Hu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 171)
DOI
10.1200/JCO.2018.36.5_suppl.171
Abstract #
171
Poster Bd #
L4
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Tumor selection and evaluation of renal cell and bladder cancer for inclusion in phase 2a expansion.
First Author: Xiao Hu
Poster
2014 ASCO Annual Meeting
Association of epithelial-mesenchymal transition status with PD1/PDL1 expression and a distinct immunophenotype in non-small cell lung cancer: Implications for immunotherapy biomarkers.
First Author: Yanyan Lou
Poster
2024 ASCO Breakthrough
Preliminary analysis of PD-1 inhibitors combined with chemotherapy as neoadjuvant therapy for local advanced non-small cell lung cancer (NSCLC).
First Author: Hongru Li
Poster
2021 ASCO Annual Meeting
Association between improvements in survival of metastatic NSCLC patients and targeted- and immuno-therapy.
First Author: Sreeram Ramagopalan